You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pembrolizumab (MK-3475)

Showing 1 - 25 of 2,147
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Pembrolizumab co-formulated with hyaluronidase
  • Pembrolizumab
  • (no location specified)
Oct 19, 2023

Hepatocellular Carcinoma Trial (Pembrolizumab)

Active, not recruiting
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • (no location specified)
Dec 15, 2022

Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

Not yet recruiting
  • Solid Tumor
  • +2 more
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Sep 7, 2023

Urothelial Cancer Trial (pembrolizumab)

Completed
Has Results
  • Urothelial Cancer
  • pembrolizumab
  • (no location specified)
Aug 18, 2022

Bladder Cancer Trial (pembrolizumab)

Active, not recruiting
  • Bladder Cancer
  • Pembrolizumab
  • +2 more
  • (no location specified)
Oct 11, 2022

Hepatocellular Carcinoma Trial (biological, drug, other)

Completed
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 30, 2022

Metastatic Castration-resistant Prostate Cancer Trial (Pembrolizumab, Enzalutamide)

Completed
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Aug 16, 2022

Renal Cell Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • (no location specified)
Aug 17, 2022

Melanoma Trial (pembrolizumab, )

Active, not recruiting
Has Results
  • Melanoma
  • pembrolizumab
  • placebo
  • (no location specified)
Aug 18, 2022

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Recurrent Head Neck Cancer, Metastatic Head Neck Cancer Trial (Pembrolizumab, Cisplatin, Carboplatin)

Active, not recruiting
Has Results
  • Recurrent Head and Neck Cancer
  • Metastatic Head and Neck Cancer
  • Pembrolizumab
  • +4 more
  • (no location specified)
Aug 18, 2022

Endometrial Cancer Trial in Oklahoma City (Pembrolizumab, Vaginal cuff brachytherapy (VCB), Paclitaxel)

Recruiting
  • Endometrial Cancer
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Jan 9, 2023

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

NSCLC Trial (V940, Pembrolizumab, Placebo)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • V940
  • +2 more
  • (no location specified)
Oct 5, 2023

Renal Cell Carcinoma Trial (Pembrolizumab, Axitinib, Sunitinib)

Active, not recruiting
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 17, 2022

Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

Completed
Has Results
  • Head and Neck Squamous Cell Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (Azacitidine, Pembrolizumab)

Active, not recruiting
  • Melanoma and Other Malignant Neoplasms of Skin
  • Metastatic Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 31, 2022

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

Melanoma Trial in Worldwide (Pembrolizumab Dose C, Pembrolizumab Dose A, Pembrolizumab Dose B)

Active, not recruiting
  • Melanoma
  • Pembrolizumab Dose C
  • +3 more
  • Orange, New South Wales, Australia
  • +14 more
Jan 19, 2023

Tumors, Colorectal Cancer Trial in Grand Rapids, Nashville, Kirkland (MK-8353, Pembrolizumab)

Completed
  • Neoplasms
  • Colorectal Cancer
  • Grand Rapids, Michigan
  • +2 more
Dec 21, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Advanced or Metastatic Solid Tumors Trial in Toronto, Genève, Bellinzona (MK-6598, Pembrolizumab)

Recruiting
  • Advanced or Metastatic Solid Tumors
  • Toronto, Ontario, Canada
  • +2 more
Jan 19, 2023

NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • Shanghai, China
    Zhongshan Hospital Fudan University
Aug 18, 2022

Triple Negative Breast Cancer (TNBC) Trial (Pembrolizumab, Nab-paclitaxel, Paclitaxel)

Active, not recruiting
Has Results
  • Triple Negative Breast Cancer (TNBC)
  • Pembrolizumab
  • +5 more
  • (no location specified)
Jul 15, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022